ProKidney Corp. (PROK)
NASDAQ: PROK · IEX Real-Time Price · USD
2.245
-0.595 (-20.95%)
Apr 18, 2024, 10:33 AM EDT - Market open
Company Description
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States.
The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Dr. Bruce Culleton M.D. |
Contact Details
Address: 2000 Frontis Plaza Blvd., Suite 250 Winston-salem, North Carolina 27103 United States | |
| Phone | 336-999-7028 |
| Website | prokidney.com |
Stock Details
| Ticker Symbol | PROK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850270 |
| ISIN Number | KYG7S53R1049 |
| Employer ID | 98-1586514 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Timothy A. Bertram D.V.M., Ph.D. | Founder |
| Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer and Corporate Secretary |
| Dr. Bruce Culleton M.D. | Chief Executive Officer and Director |
| James Coulston CPA | Chief Financial Officer |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Senior Vice President of Investor Relations |
| Mary Weger | Chief People Officer |
| Dr. Joseph M. Stavas M.D., M.P.H. | Senior Vice President and Head of Global Clinical Development and Interventional Procedures |
| Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access |
| Nikhil L. Pereira-Kamath | Chief Business Officer |
| Richard Williams | Senior Vice President of Information Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 144 | Filing |
| Apr 12, 2024 | 144 | Filing |
| Apr 1, 2024 | 144 | Filing |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 10-K | Annual Report |
| Mar 18, 2024 | 8-K/A | [Amend] Current report |
| Mar 18, 2024 | 8-K/A | [Amend] Current report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |